Among cancer deaths worldwide, lung cancer is the leader.
It isn't just the tumor cells, the growth of blood vessels controls tumors development and blood vessel growth is controlled by several signalling molecules. Scientists have discovered a molecule, phosphodiesterase PDE4, that plays a key role in this process and they have succeeded in reducing tumor growth in their experiments by blocking it.
While lung cancer is commonly linked to smokers, it can also be caused by contact with carcinogenic substances like asbestos and then some random mutations just happen. Chemotherapy or radiotherapy often prove insufficient in treating lung cancer so scientists have been engaged in an intensive search for ways of halting the growth of lung tumors. The blood vessels that supply the tumor with nutrients offer a potential point of attack.
New blood vessels form to ensure an adequate supply of nutrients to the growing tumor. The growing tissue is immediately penetrated by blood vessels. The growth of the blood vessels is regulated by the tumor cells using a complex signal cascade, which is triggered initially by a low oxygen content (hypoxia) in the tumor tissue. “This state, which is known as hypoxia prompts the activation of around 100 genes in the tumor cells,” explains Rajkumar Savai, research group leader at the Max Planck Institute of Biochemistry in Martinsried. “In addition to the growth of blood vessels, hypoxia also stimulates the proliferation of lung cancer cells.”
Three molecules play a particularly important role in this process. The activation of the genes at the beginning of the cascade is triggered by the transcription factor HIF and a messenger molecule, cAMP, is involved again at the end of the cascade. The researchers examined the third molecule that acts as a link between these two molecules in detail, phosphodiesterase PDE4.
Formation of PDE4 in oxygen-deficient lung tumor cells. Lung cells produce PDE4 (stained green: left) even if their oxygen content is normal. More PDE4 is produced (right) if they are oxygen-deficient (hypoxia). The cell nuclei are stained blue. Credit: MPI for Heart and Lung Research
The scientists from Bad Nauheim and Giessen were able to demonstrate in their study that various sections of PDE4 have binding sites for HIF.
The researchers then tested the influence of a PDE4 blockade on the cells from ten different cell lines, which are characteristic of around 80 percent of lung cancers, in the laboratory. The rate of cell division in the cells treated with a PDE4 inhibitor was significantly lower and the HIF level also declined as a result.
The effect in the tumor-bearing mice was particularly obvious. To observe this, the Max Planck researchers implanted a human tumor cell line under the skin of nude mice and treated the animals with the phosphodiesterase 4 inhibitor. Tumor growth in these animals declined by around 50 percent. “Our microscopic analysis revealed that the blood vessel growth in the tumours of the mice that had been treated with the inhibitor was significantly reduced. We also observed indicators of decelerated cell division in the tumor cells. Overall, the tumor growth was strongly curbed.”
Werner Seeger, Director of the MPI and Medical Director of the JLU University Hospital Giessen, said, “We were able to show that PDE4 plays an important regulation function in cell division in lung tumours and in the development of blood vessels in cancer. Therefore, we hope that we have found a starting point for the development of a treatment here.”
In the view of tumor specialist Friedrich Grimminger, Chairman of the Department of Medical Oncology in Giessen, it may be possible in future to combine the inhibition of PDE4 with traditional radiotherapy or chemotherapy. In this way, the effect of the traditional treatment measures could be reinforced and patient prognoses may improve as a result. However, further laboratory studies are required before clinical tests can be carried out.
Citation: S. Pullamsetti, G. Banat, A. Schmall, M. Szibor, D. Pomagruk, J. Hänze, E. Kolosionek, J. Wilhelm, T. Braun, F. Grimminger, W. Seeger, R. Schermuly, R. Savai: Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene (2012). doi:10.1038/onc.2012.136
It isn't just the tumor cells, the growth of blood vessels controls tumors development and blood vessel growth is controlled by several signalling molecules. Scientists have discovered a molecule, phosphodiesterase PDE4, that plays a key role in this process and they have succeeded in reducing tumor growth in their experiments by blocking it.
While lung cancer is commonly linked to smokers, it can also be caused by contact with carcinogenic substances like asbestos and then some random mutations just happen. Chemotherapy or radiotherapy often prove insufficient in treating lung cancer so scientists have been engaged in an intensive search for ways of halting the growth of lung tumors. The blood vessels that supply the tumor with nutrients offer a potential point of attack.
New blood vessels form to ensure an adequate supply of nutrients to the growing tumor. The growing tissue is immediately penetrated by blood vessels. The growth of the blood vessels is regulated by the tumor cells using a complex signal cascade, which is triggered initially by a low oxygen content (hypoxia) in the tumor tissue. “This state, which is known as hypoxia prompts the activation of around 100 genes in the tumor cells,” explains Rajkumar Savai, research group leader at the Max Planck Institute of Biochemistry in Martinsried. “In addition to the growth of blood vessels, hypoxia also stimulates the proliferation of lung cancer cells.”
Three molecules play a particularly important role in this process. The activation of the genes at the beginning of the cascade is triggered by the transcription factor HIF and a messenger molecule, cAMP, is involved again at the end of the cascade. The researchers examined the third molecule that acts as a link between these two molecules in detail, phosphodiesterase PDE4.
Formation of PDE4 in oxygen-deficient lung tumor cells. Lung cells produce PDE4 (stained green: left) even if their oxygen content is normal. More PDE4 is produced (right) if they are oxygen-deficient (hypoxia). The cell nuclei are stained blue. Credit: MPI for Heart and Lung Research
The scientists from Bad Nauheim and Giessen were able to demonstrate in their study that various sections of PDE4 have binding sites for HIF.
The researchers then tested the influence of a PDE4 blockade on the cells from ten different cell lines, which are characteristic of around 80 percent of lung cancers, in the laboratory. The rate of cell division in the cells treated with a PDE4 inhibitor was significantly lower and the HIF level also declined as a result.
The effect in the tumor-bearing mice was particularly obvious. To observe this, the Max Planck researchers implanted a human tumor cell line under the skin of nude mice and treated the animals with the phosphodiesterase 4 inhibitor. Tumor growth in these animals declined by around 50 percent. “Our microscopic analysis revealed that the blood vessel growth in the tumours of the mice that had been treated with the inhibitor was significantly reduced. We also observed indicators of decelerated cell division in the tumor cells. Overall, the tumor growth was strongly curbed.”
Werner Seeger, Director of the MPI and Medical Director of the JLU University Hospital Giessen, said, “We were able to show that PDE4 plays an important regulation function in cell division in lung tumours and in the development of blood vessels in cancer. Therefore, we hope that we have found a starting point for the development of a treatment here.”
In the view of tumor specialist Friedrich Grimminger, Chairman of the Department of Medical Oncology in Giessen, it may be possible in future to combine the inhibition of PDE4 with traditional radiotherapy or chemotherapy. In this way, the effect of the traditional treatment measures could be reinforced and patient prognoses may improve as a result. However, further laboratory studies are required before clinical tests can be carried out.
Citation: S. Pullamsetti, G. Banat, A. Schmall, M. Szibor, D. Pomagruk, J. Hänze, E. Kolosionek, J. Wilhelm, T. Braun, F. Grimminger, W. Seeger, R. Schermuly, R. Savai: Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene (2012). doi:10.1038/onc.2012.136
